Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lotiglipron
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lotiglipron is an oral, small-molecule, non-peptide glucagon-like peptide-1 receptor (GLP-1R) agonist developed by Pfizer for the treatment of type 2 diabetes and obesity. It was designed to mimic the effects of endogenous GLP-1, stimulating insulin secretion in response to meals, inhibiting glucagon secretion to reduce hepatic glucose output, slowing gastric emptying to promote satiety and weight loss, and ultimately lowering blood sugar levels. Lotiglipron demonstrated dose-dependent reductions in glycated hemoglobin (HbA1c) and body weight in clinical trials. However, its development was terminated after early-stage studies revealed elevated liver enzymes indicative of potential liver toxicity[1][2][5][6][7].
02
Targets
Beyond the preview
Go deeper on lotiglipron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lotiglipron.